An experienced endocrinologist, Victor L. Roberts, MD, has operated Lake Mary’s Endocrine Associates of Florida since 1988. Victor L. Roberts, MD, is a staunch advocate for gliflozins in the management of diabetes with the extra advantage of assisting with cardiac disease
Clinically known as “sodium-glucose co-transporter-2” or “SGLT2” inhibitors, gliflozins have proven useful in the treatment of type 2 diabetes for roughly two decades. They function by boosting the natural ability of the kidneys to lower glucose levels in the bloodstream. Today, a growing number of clinical specialists are advocating for the management of gliflozins in patients with heart failure and other cardiovascular issues. For example, on May 26, 2022, the New England Journal of Medicine published the article “Gliflozins in the Management of Cardiovascular Disease” by Eugene Braunwald. This article recognizes the ability of gliflozins to lower blood glucose without causing hypoglycemia. It concludes that gliflozins can safely increase cardiac function in heart failure patients regardless of any type 2 diabetes diagnosis.
0 Comments
Leave a Reply. |
AuthorDr. Victor Roberts Archives
September 2021
CategoriesAll Community Outreach Covid-19 Cushing’s Syndrome Diabetes Health Hormonal Causes Hypothyroidism Urination Victor L Roberts MD |